Attitudes towards COVID‑19 vaccination in patients with cancer: A cross‑sectional study of 12 oncology centers.
COVID-19 infection
COVID-19 vaccination
patients with cancer
social platforms
vaccine hesitancy
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
02
08
2022
accepted:
23
09
2022
entrez:
8
12
2022
pubmed:
9
12
2022
medline:
9
12
2022
Statut:
epublish
Résumé
Patients with cancer are a high-priority population for COVID-19 vaccination, as per guideline recommendations. The present cross-sectional study was performed to assess the perception of patients with cancer from Romania regarding COVID-19 vaccines. The study included 932 patients with solid and hematologic malignancies. This was a multicenter study including 12 oncology centers located in Western and Northwestern Romania. Between December 2021 and January 2022, patients with cancer completed an individual paper questionnaire regarding acceptance of the SARS-CoV-2 vaccination, type of vaccine, side effects and source of information. During the first year of the vaccination campaign in Romania, 58.05% (541/932) of the investigated patients received COVID-19 vaccines. The vaccination rate was highest in the 61-70 year age group (61.22%). The most frequently used vaccine was Pfizer-BioNTech (72%). There was a statistically significant association between the rate of vaccination and the area of residence and level of education (P<0.001), with rural residence and a lower level of education being predictive factors for COVID-19 vaccination hesitancy. Patients living in rural areas used non-medical sources (e.g. mass media, social platforms) as their main source of information (53.40%, 204/382), whereas patients living in urban areas (64.90%, 357/550) used predominantly medical sources (e.g. recommendations from oncologists and general practitioners). The main source of information among non-vaccinated patients was mass media (e.g. television, radio); 72.38% vs. 29.67% among vaccinated patients. For the latter, the primary source of information was the recommendations made by oncologists (59.70%) and general practitioners (56.76%). The most commonly reported side effect was injection site pain (20-33% for the first dose and 5-27% for the second dose). In conclusion, the present study confirmed that patients with cancer may be reluctant to receive a COVID-19 vaccine, mainly due to the fear of its potential side effects. Although there is scientific evidence to support the efficacy and safety of vaccines, the primary source of information for patients may affect vaccine uptake, thus affecting the efforts to stop the pandemic. Furthermore, the present study revealed that non-vaccinated patients preferred mass media as their main source of information, whereas vaccinated patients relied on the recommendations made by oncologists or general practitioners.
Identifiants
pubmed: 36479255
doi: 10.3892/mco.2022.2595
pii: MCO-17-6-02595
pmc: PMC9716118
doi:
Types de publication
Journal Article
Langues
eng
Pagination
162Informations de copyright
Copyright: © Lazar et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1342-1348
pubmed: 35470920
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Front Public Health. 2021 Aug 13;9:698111
pubmed: 34485229
Breast. 2021 Dec;60:214-222
pubmed: 34736092
Am J Med. 2021 Feb;134(2):176-181
pubmed: 32979306
Vaccines (Basel). 2021 Jul 16;9(7):
pubmed: 34358208
Vaccines (Basel). 2022 Mar 08;10(3):
pubmed: 35335040
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Healthcare (Basel). 2021 Mar 19;9(3):
pubmed: 33808758
JAMA Oncol. 2021 Aug 1;7(8):1242-1244
pubmed: 34110371
Support Care Cancer. 2022 May;30(5):4565-4570
pubmed: 35119521
Eur J Epidemiol. 2020 Aug;35(8):775-779
pubmed: 32785815
Vaccine. 2017 Oct 27;35(45):6059-6069
pubmed: 28974409
Eur J Cancer. 2021 Sep;155:54-55
pubmed: 34352570
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
J BUON. 2021 Sep-Oct;26(5):2183-2190
pubmed: 34761633
Ann Oncol. 2021 May;32(5):673-674
pubmed: 33529740
Ann Oncol. 2021 May;32(5):579-581
pubmed: 33582237
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
ESMO Open. 2021 Feb;6(1):100027
pubmed: 33399089
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Mayo Clin Proc. 2015 Nov;90(11):1562-8
pubmed: 26541249
Vaccines (Basel). 2022 Feb 09;10(2):
pubmed: 35214719